What is Boundless Bio?
Boundless Bio is a next-generation precision oncology company dedicated to exploring a novel area of cancer biology: extrachromosomal DNA (ecDNA). By targeting ecDNA, the company aims to deliver transformative therapies to patients suffering from oncogene-amplified cancers. This focus positions Boundless Bio at the forefront of innovative cancer treatment research, seeking to address a critical unmet need in the oncology landscape. The company's scientific approach is rooted in understanding and exploiting unique genetic mechanisms driving cancer progression.
How much funding has Boundless Bio raised?
Boundless Bio has raised a total of $251.4M across 3 funding rounds:
Series A
$46.4M
Series B
$105M
Series C
$100M
Series A (2019): $46.4M with participation from ARCH Venture Partners, City Hill Ventures, GT Healthcare Capital Partners, Boxer Capital, Vertex Ventures, and Alexandria Venture Investments
Series B (2021): $105M led by Surveyor Capital, Wellington Management, PFM Health Sciences, RA Capital Management, Redmile Group, Fidelity Management & Research Company, Nextech Invest, and Logos Capital
Series C (2023): $100M supported by Sectoral Asset Management, RA Capital Management, and Bayer
Key Investors in Boundless Bio
RA Capital Management
RA Capital Management is a multi-stage investment manager focused on evidence-based investing in public and private healthcare and life science companies, including those developing drugs, medical devices, diagnostics, and research tools. RA Capital aims to partner with innovators to bring ideas from the lab to the clinic, ultimately improving patient lives.
Nextech Invest
Nextech Invest is a Zurich-based company dedicated to accelerating advancements in precision medicine by identifying transformative cancer medicines. They focus on nurturing emerging biotechnology companies worldwide, particularly during critical moments of scientific validation and value creation.
ARCH Venture Partners
ARCH Venture Partners is a leading earlystage venture capital firm that creates and invests in life sciences and advanced technology companies, often cofounding startups with scientists and entrepreneurs to commercialize innovations from universities, corporate R&D groups, and national laboratories.
What's next for Boundless Bio?
With the recent influx of major strategic investment, Boundless Bio is poised for accelerated growth and the advancement of its therapeutic pipeline. This substantial capital infusion is expected to fuel further research and development, potentially enabling the company to move its ecDNA-targeting therapies closer to clinical trials and eventual patient access. The ongoing support from prominent investors suggests a strategic focus on scaling operations and solidifying its position in the competitive precision oncology market. Boundless Bio's trajectory indicates a commitment to translating cutting-edge scientific discovery into tangible patient benefits.
See full Boundless Bio company page
